Literature DB >> 22339992

Managing pathologic aggression in people with psychotic disorders.

Dominique Bourget1, Alain Labelle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22339992      PMCID： PMC3297069          DOI： 10.1503/jpn.110174

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  23 in total

1.  Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.

Authors:  J Munro; D O'Sullivan; C Andrews; A Arana; A Mortimer; R Kerwin
Journal:  Br J Psychiatry       Date:  1999-12       Impact factor: 9.319

2.  A meta-analysis of the efficacy of second-generation antipsychotics.

Authors:  John M Davis; Nancy Chen; Ira D Glick
Journal:  Arch Gen Psychiatry       Date:  2003-06

3.  Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

Authors:  Philip Shaw; Alex Sporn; Nitin Gogtay; Gerald P Overman; Deanna Greenstein; Peter Gochman; Julia W Tossell; Marge Lenane; Judith L Rapoport
Journal:  Arch Gen Psychiatry       Date:  2006-07

4.  Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms.

Authors:  Shih-Ku Lin; Sheng-Fen Su; Chun-Hung Pan
Journal:  Ther Drug Monit       Date:  2006-06       Impact factor: 3.681

Review 5.  Optimizing clozapine treatment.

Authors:  J Nielsen; P Damkier; H Lublin; D Taylor
Journal:  Acta Psychiatr Scand       Date:  2011-04-28       Impact factor: 6.392

6.  Clozapine treatment associated with increased risk of acute myeloid leukemia (AML).

Authors:  Jimmi Nielsen; Anders Boysen
Journal:  Schizophr Res       Date:  2010-09-17       Impact factor: 4.939

7.  Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Authors:  Robert M Bilder; Robert S Goldman; Jan Volavka; Pal Czobor; Matthew Hoptman; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Michal Kunz; Miranda Chakos; Thomas B Cooper; Terri L Horowitz; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2002-06       Impact factor: 18.112

Review 8.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

9.  Increased use of antibiotics in patients treated with clozapine.

Authors:  Jimmi Nielsen; Leslie Foldager; Jonathan M Meyer
Journal:  Eur Neuropsychopharmacol       Date:  2009-04-07       Impact factor: 4.600

10.  Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.

Authors:  Menahem I Krakowski; Pal Czobor; Karen A Nolan
Journal:  J Clin Psychopharmacol       Date:  2008-10       Impact factor: 3.153
View more
  1 in total

Review 1.  Guidelines for the Pharmacotherapy of Schizophrenia in Adults.

Authors:  Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan
Journal:  Can J Psychiatry       Date:  2017-07-13       Impact factor: 4.356
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.